Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Glioma 2Glioblastoma 2Cholangiocarcinoma 2Spinal Cord Neoplasms 1Oligodendroglioma 1Neoplasms 1Leukemia, Myeloid, Acute 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Bile Duct Neoplasms 1Astrocytoma 1

Interventions

Nivolumab 2Cisplatin 2Capecitabine 2tipifarnib 1olutasidenib 1entinostat 1Trastuzumab 1Thalidomide 1Specimen Handling 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Observation 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Leucovorin 1Irinotecan 1Ipilimumab 1Immunotherapy 1Gemcitabine 1Floxuridine 1Fentanyl 1Erlotinib Hydrochloride 1Epirubicin 1Drug Therapy 1Docetaxel 1Cetuximab 1Carboplatin 1CTLA-4 Antigen 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × olutasidenib × CNS × Clear all
NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
93 enrolled 24 charts
CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡